MIL OSI Translation. Region: Germany / Germany –
Source: BayerLeverkusen, September 10, 2019 – At its meeting on Tuesday, the Supervisory Board of Bayer AG decided to reduce the size of the company’s Management Board from currently seven to then five, with effect from January 1, 2020. Dr. Hartmut Klusik (63) and Kemal Malik (56) will leave the company on December 31, 2019. The two Executive Board positions will not be filled as part of the announced efficiency measures. “The Supervisory Board thanks Dr. med. Hartmut Klusik and Kemal Malik for many years of successful work at Bayer. With their commitment and expertise, they have earned great services to their respective areas of responsibility as well as to the company as a whole, “said Werner Wenning, Chairman of the Supervisory Board of Bayer AG. “By streamlining the Executive Board organization, we are optimizing the way responsibilities are tailored and thus contributing to the Group’s ongoing efficiency program. Innovation and technology as well as the further development of our network of partnerships will continue to be the decisive success factors of our company and be anchored in the management organization. “As of January 1, 2020, the Management Board of Bayer AG will consist of CEO Werner Baumann, CFO Wolfgang Nickl and Liam Condon (Crop Science) responsible for the divisions, Stefan Oelrich (Pharmaceuticals) and Heiko Schipper (Consumer Health). Hartmut Klusik has been a member of the Executive Board since January 2016 and is responsible for Human Resources, Technology and Sustainability. He is also Labor Director of Bayer AG. Kemal Malik has been a member of the board since February 2014 and is responsible for innovation and the Asia Pacific region. Their tasks will be reassigned: The topics of personnel and sustainability and “Leaps by Bayer” – an organizational unit that makes early investments in technologies with groundbreaking potential – will in future be led by CEO Werner Baumann. Baumann will also take on the role of labor director. The division “Engineering and Technology” reports to CFO Wolfgang Nickl. “We have the always open and constructive exchange on equal terms with Dr. Ing. Klusik much appreciated – even if we did not always agree. In dealing with our colleagues, credibility and appreciation are the immutable basis. As Chairman of the Management Board, Mr. Baumann stands for these values. We insist that this also applies to his role as Labor Director, “said Oliver Zühlke, Chairman of Bayer’s General Works Council. The divisions will in future be responsible for the entire value chain from research and development to production and marketing. The cross-cutting issues of quality and health protection, safety and the environment are assigned to the divisions. Responsibilities for the regions will also be rearranged: Stefan Oelrich will be responsible for Europe / Middle East, Wolfgang Nickl for North America, Liam Condon for Latin America and Africa, Heiko Schipper for Asia / Pacific.About BayerBayer, a global player with core competencies in the Life Science Health and Nutrition. With its products and services, the company aims to benefit people by helping to solve the fundamental challenges of a steadily growing and aging world population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainability and stands for trust, reliability and quality worldwide with its brand. In the financial year 2018, the Group achieved sales of 39.6 billion euros with around 117,000 employees. Investments amounted to € 2.6 billion and R & D spending to € 5.2 billion. Further information can be found on the internet at www.bayer.deFollow us on Twitter: twitter.com/BayerPresse_USFor Forward Looking StatementsThis press release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors may cause the actual results, financial position, development or performance of the Company to differ materially from the estimates given here. These factors include those described by Bayer in published reports. These reports are available on the Bayer website www.bayer.de. The Company assumes no obligation to update such forward-looking statements and to adapt them to future events or developments.
EDITOR’S NOTE: This article is a translation. Apologies should the grammar and/or sentence structure need be perfect.